Skip to main content
For doctors
Phase 3 RecruitingInfectious Diseases

Alimatravir (MK-8527), EXPrESSIVE

Once-monthly oral HIV-1 pre-exposure prophylaxis

Sponsor: Merck (MSD)

  • 8,970Enrollment target
  • N/ATrial sites
  • N/ACountries
  • July 2027Est. completion
  • NCT07044297Registry record

About this trial

A once-monthly pill would be the first oral alternative to injectable long-acting PrEP.

Primary endpoints

  • Incidence of HIV-1 infection

Latest update

July 2026

Merck announced initial access plans for alimatravir, an investigational once-monthly oral HIV pre-exposure prophylaxis still in Phase 3 — unusually early access planning for a pre-approval asset. The two Phase 3 studies read out in July and October 2027.

Source

Trial information is compiled from public sources and may be out of date. It is not medical advice and is not an offer of enrolment; check the registry entry or speak to a physician before acting on it.